New Gene Therapy Strategies for the Deletion of Exon 44 of Dystrophin Gene Based on Gene Editing by TALENs

Ping Li, Yunzhi Pan, Alice S. S. Li, Aijuan Sun, Jia Zhang, H. L. Gao, Pierre Sirois, Kai Li

Centre Hospitalier de l’Université Laval Research Center, Laval University, Quebec, Canada.
Department of Molecular Diagnostics and Biopharmaceutics, College of Pharmaceutical Science, Soochow University, Suzhou, China.
DNA Sequencing Core Laboratory, City of Hope National Medical Center, Duarte, USA.
Gene Core, The Genomics Institute of the Novartis Research Foundation, San Diego, USA.
University of Waterloo, Waterloo, Canada.

DOI: 10.4236/ojmc.2013.31001                

Abstract

Duchenne Muscular Dystrophy (DMD) is a severe childhood form of muscular dystrophy. Both the severe form and its milder form of Becker Muscular Dystrophy (BMD) are caused by the mutation of dystrophin gene. Different from some other genetic diseases such as hemophilia that can be treated by replacement therapy, there is no effective therapy for muscular dystrophy in conventional medication. Gene editing technology from the recently developed engineered nucleases such as TALENs has been successfully employed in genome modification of a variety of species, and will be applied in gene therapy of selected human diseases. The genetic basis of DMD and BMD indicates that DMD is a good target for gene therapy through returning the reading frame of dystrophin gene. Gene therapy strategies described here may apply to many other genetic diseases. Wider application of TALENs in gene therapy have the potential to dramatically prolong the lifespan of individuals with genetic diseases.

Keywords

TALENs; DMD; Gene Therapy; Exon Skipping

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Natalie de Souza, “Zinc-Finger Nucleases,” Nature Methods, Vol. 8, No. 1, 2011, p. 43.
[2]	M. J. Moscou and A. J. Bogdanove, “A Simple Cipher Governs DNA Recognition by TAL Effectors,” Science, Vol. 326, No. 5959, 2009, p. 1051. doi:10.1126/science.1178817
[3]	J. Boch, H. Scholze and S. Schornack, “Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors,” Science, Vol. 326, No. 5959, 2009, pp. 10509-10512. doi:10.1126/science.1178811
[4]	R. Morbitzer, P. R?mer and J. Boch, “Regulation of Selected Genome Loci Using de Novo-Engineered Transcription Activator-Like Effector (TALE)-Type Transcription Factor,” Proceedings of the National Academy of Sciences of the United States, Vol. 107, No. 50, 2010, pp. 21617-21622. doi:10.1073/pnas.1013133107
[5]	R. Geissler, H. Scholze and S. Hahn, “Transcriptional Activators of Human Genes with Programmable DNASpecificity,” PLoS One, Vol. 6, No. 5, 2011, Article ID: e19509. doi:10.1371/journal.pone.0019509
[6]	M Christian, T Cermak and EL Doyle, “Targeting DNA Double-Strand Breaks with TAL Effector Nucleases,” Genetics, Vol. 186, No. 2, 2010, pp. 757-61. doi:10.1534/genetics.110.120717
[7]	M. M. Mahfouz, L. Li and M. Shamimuzzaman, “De Novo-Engineered Transcription Activator-Like Effector (TALE) Hybrid Nuclease with novel DNA Binding Specificity Creates Double-Strand Breaks,” Proceedings of the National Academy of Sciences of the United States, Vol. 108, No. 6, 2011, pp. 2623-2628. doi:10.1073/pnas.1019533108
[8]	J. C. Miller, S. Tan and G. Qiao, “A TALE Nuclease Architecture for Efficient Genome Editing,” Nature Biotechnology, Vol. 29, No. 2, 2011, pp. 143-148. doi:10.1038/nbt.1755
[9]	P. Huang, A. Xiao and M. Zhou, “Heritable Gene Targeting in Zebrafish Using Customized TALENs,” Nature Biotechnology, Vol. 29, No. 8, 2011, pp. 699-700. doi:10.1038/nbt.1939
[10]	G. Silva, L. Poirot and R. Galetto, “Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene Therapy,” Current Gene Therapy, Vol. 11, No. 1, 2011, pp. 11-27. doi:10.2174/156652311794520111
[11]	D Hockemeyer, H Wang and S Kiani, “Genetic Engineering of Human Pluripotent Cells Using TALE Nucleases,” Nature Biotechnology, Vol. 29, No. 8, 2011, pp. 731-734. doi:10.1038/nbt.1927
[12]	H. Li, V. Haurigot and Y. Doyon, “In Vivo Genome Editing Restores Haemostasis in a Mouse Model of Haemophilia,” Nature, Vol. 475, No. 7355, 2011, pp. 217-221. doi:10.1038/nature10177
[13]	J. A. Townsend, D. A. Wright and R. J. Winfrey, “HighFrequency Modification of Plant Genes Using Engineered Zinc-Finger Nucleases,” Nature, Vol. 459, No. 7245, 2011, pp. 442-445. doi:10.1038/nature07845
[14]	K. Osakabe, Y. Osakabe and S. Toki, “Site-Directed Mutagenesis in Arabidopsis Using Custom-Designed Zinc Finger Nucleases,” Proceedings of the National Academy of Sciences of the United States,Vol. 107, No. 26, 2010, pp. 12034-12039. doi:10.1073/pnas.1000234107
[15]	A. D. Goldberg, L. A. Banaszynski and K. M. Noh, “Distinct Factors Control Histone Variant H3.3 Localization at specific Genomic Regions,” Cell, Vol. 140, No. 5, 2010, pp. 678-691. doi:10.1016/j.cell.2010.01.003
[16]	J. R. Mendell, C. Shilling and N. D. Leslie, “EvidenceBased Path to Newborn Screening for Duchenne Muscular Dystrophy,” Annals of Neurology, Vol. 73, No. 4, 2012, pp. 304-313. doi:10.1002/ana.23528
[17]	J. Oshima, D. B. Magner and J. A. Lee, “Regional Genomic Instability Predisposes to Complex Dystrophin Gene Rearrangements,” Human Genetics Vol. 126, No. 3, 2009, pp. 411-423. doi:10.1007/s00439-009-0679-9
[18]	L. L. Baumbach, J. S. Chamberlain and P. A. Ward, “Molecular and Clinical Correlation of Deletion Leading to Duchenne and Becker Muscular Dystrophies,” Neurology, Vol. 39, No. 4, 1989, pp. 465-474. doi:10.1212/WNL.39.4.465
[19]	A. Pizzuti, M. Pieretti and R. G. Fenwick, “A Transposon-Like Element in the Deletion-Prone Region of the Dystrophin Gene,” Genomics, Vol. 13, No. 3, 1992, pp. 594-600. doi:10.1016/0888-7543(92)90129-G
[20]	Z. Lu, “Interaction of Nonsense Suppressor tRNAs and Codon Nonsense Mutations or Termination Codons,” Advances in Biological Chemistry, Vol. 2, No. 3, 2012, pp. 301-314. doi:10.4236/abc.2012.23038
[21]	J. F. Burke and A. E. Mogg, “Suppression of a Nonsense Mutation in Mammalian Cells in vivo by the Aminoglycoside Antibiotics G-418 and Paromomycin,” Nucleic Acids Research, Vol. 13, No. 17, 1985, pp. 6265-6272. doi:10.1093/nar/13.17.6265
[22]	C. Bertoni, C. Lau and T. A. Rando, “Restoration of Dystrophin Expression in Mdx Muscle Cells by Chimeraplast-Mediated Exon Skipping,” Human Molecular Genetics, Vol. 12, No. 10, 2003, pp. 1087-1099. doi:10.1093/hmg/ddg133
[23]	J. Alter, F. Lou and A. Rabinowitz, “Systemic Delivery of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide and Improves Dystrophic Pathology,” Nature Medicine, Vol. 12, No. 2, 2006, pp. 175-177. doi:10.1038/nm1345
[24]	T. Yokota, Q. L. Lu and T. Partridge, “Efficacy of Systemic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs,” Annals of Neurology, Vol. 65, No. 6, 2009, pp. 667-676. doi:10.1002/ana.21627
[25]	C. J. Klein, D. D. Coovert and D. E. Bulman, “Somatic Reversion/Suppression in Duchenne Muscular Dystrophy (DMD): Evidence Supporting a Frame-Restoring Mechanism in Rare Dystrophin-Positive Fibers,” The American Journal of Human Genetics, Vol. 50, No. 5, 1992, pp. 950-959.
[26]	J. R. Mendell, L. Rodino-Klapac and Z. Sahenk, “Gene Therapy for Muscular Dystrophy: Lessons Learned and Path Forward,” Neuroscience Letters, Vol. 527, No. 2, 1992, pp. 90-99. doi:10.1016/j.neulet.2012.04.078
[27]	J. Zhang, L. Xiao and Y. Yin, “A Law of Mutation: Power Decay of Small Insertions and Small Deletions Associated with Human Diseases,” Applied Biochemistry and Biotechnology, Vol. 162, No. 2, 2010, pp. 321-328. doi:10.1007/s12010-009-8793-7
[28]	L. Xiao, W. Sun and J. Zhang, “An Excess of G over C Nucleotides in Mutagenesis of Human Genetic Diseases,” Molecular Biotechnology, Vol. 48, No. 1, 2011, pp. 1-6. doi:10.1007/s12033-010-9341-y